Piramal Pharma has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Turbhe facility with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection.
Earlier, the USFDA had conducted General Good Manufacturing Practices (GMP) inspection at company’s Turbhe facility from February 11, 2025 to February 17, 2025.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
